The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.
Klassen, Stephen A. PhD a; Senefeld, Jonathon W. PhD a; Johnson, Patrick W. BSc e; Carter, Rickey E. PhD e; Wiggins, Chad C. PhD a; Shoham, Shmuel MD g; Grossman, Brenda J. MD h; Henderson, Jeffrey P. MD, PhD i, j; Musser, James MD, PhD k, l, m; Salazar, Eric MD, PhD k, m; Hartman, William R. MD n; Bouvier, Nicole M. MD o, p; Liu, Sean T.H. MD, PhD o, p; Pirofski, Liise-anne MD q; Baker, Sarah E. PhD a; van Helmond, Noud MD r; Wright, Scott R. MD b, c; Fairweather, DeLisa PhD f; Bruno, Katelyn A. PhD f; Wang, Zhen PhD d; Paneth, Nigel S. MD s, t; Casadevall, Arturo MD, PhD u; Joyner, Michael J. MD a, *
[Review]
Mayo Clinic Proceedings.
96(5):1262-1275, May 2021.
(Format: HTML, PDF)
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.
(C) 2021 Mayo Foundation for Medical Education and Research
